Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease

Liver Transplantation

Volumn 12, Issue 1, 2006, Pages 124-133

  Dickson, Rolland C ^a   Terrault, Norah A ^b   Ishitani, Michael ^a   Reddy, K Rajender ^c,m   Sheiner, Patricia ^d,n   Luketic, Velimir ^e   Soldevila Pico, Consuelo ^f   Fried, Michael ^g   Jensen, Donald ^h   Brown Jr , Robert S ⁱ   Horwith, Gary ^j   Brundage, Richard ^k   Lok, Anna ^l  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ New York Presbyterian Hospital Columbia University Medical Center   (United States)

^j Columbia Presbyterian Medical Center ^*  (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

^l UNIVERSITY OF MICHIGAN   (United States)

^m HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ WESTCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ANOREXIA; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HALF LIFE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEPATITIS; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; MALAISE; MALE; NAUSEA; PERITONITIS; PRIORITY JOURNAL; RECURRENT INFECTION; SEPSIS; VIRUS REPLICATION;

ADULT; AGED; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B ANTIBODIES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS; INFUSIONS, INTRAVENOUS; LAMIVUDINE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 33645101410     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20582     Document Type: Article

References (33)

1. Van Thiel DH, Schade RR, Gavaler JS, Shaw BW, Jr., Iwatsuki S, Starzl TE. Medical aspects of liver transplantation. Hepatology 1984;4:79S-83S.
2. Lake JR. Should liver transplantation be performed for patients with chronic hepatitis B? Yes! Liver Transpl Surg, 1995;1:260-265.
3. Todo S, Demetris AJ, Van TD, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13: 619-26.
4. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813-815.
5. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: serological and clinical implications. J Hepatol 1992;14:104-111.
6. Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 1987;19:4051-4053.
7. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
8. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-1333.
9. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358-1364.
10. Wright TL. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis 2004;24: 31-36.
11. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-432.
12. Mutimer, D., Lamivudine for hepatitis B after liver transplantation. Liver Transpl, 2001;7:511-512.
13. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125: 1714-1722.
14. Malkan G, Cattral MS, Humar A, Al AH, Greig PD, Hemming AW, et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation, 2000;69:1403-1407.
15. Seehofer D, Rayes N, Steinmuller T, Muller AR, Settmacher U, Neuhaus R, et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001;7:976-982.
16. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741-748.
17. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Boker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34:895-902.
18. Roche B, Samuel D. Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. J Hepatol 2003;39:S181-S189.
19. Seehofer D, Rayes N, Steinmuller T, Muller AR, Jonas S, Settmacher U, et al. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol 2002;40:795-799.
20. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy RF, Gish RR. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999;5:491-496.
21. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999;5:520-525.
22. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429-433.
23. Marzano A, Salizzoni M, Bernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-910.
24. Samuel, D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004;24:55-62.
25. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
27. Group NP. NONMEM users guides 1992. Boeckmann AJ, Sheiner LB, eds. San Francisco: University of California at San Francisco, 1992.
28. Partovi N, Guy MW, Ensom MH, Noble MA, Yoshida EM. A study of the pharmacokinetic profile of low-dose hepatitis B immune globulin in long-term liver transplant recipients for chronic hepatitis B infection. Am J Transplant 2001;1:51-54.
29. Yao FY, Terrault NA, Freise C, Maslow L, Base NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:411-416.
30. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210.
31. Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. [See comment.] J Hepatol 2000;33:308-312.
32. al-Hemsi B, McGory RW, Shepard B, Ishitani MB, Stevenson WC, McCullough C, Pruett TL. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant, 1996;10:668-675.
33. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10:S74-S85.